NewsRoom Articles - Page 42 of 225

WednesdayAug 28, 2024 9:00 am

Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast

Clene is pioneering a very unique approach to the treatment of neurodegenerative diseases such as ALS and MS with the use of an oral nanotherapeutic that can be easily administered The company has submitted CNM-Au8 biomarker and efficacy data to the Food and Drug Administration in a Type C meeting request, seeking approval to file a new drug application using the accelerated approval pathway for ALS CNM-Au8 has the potential to impact the ALS therapeutic market, as CNM-Au8 can help increase and improve survival rates and delay clinical worsening in ALS patients In MS, CNM-Au8 can work in conjunction with…

TuesdayAug 27, 2024 10:00 am

AI Firms Gain Foothold in e-Commerce, Software, Healthcare Industries

Artificial intelligence (AI) seems to be making a mark on different industries, with some companies even recording growth in the healthcare and retail sectors. These companies are using artificial intelligence to address issues in these sectors, from rising medical bills to sizing issues in e-commerce. This indicates a possible shift in how industries are approaching different problems. One provider of AI-driven measurement solutions for e-commerce, MySize Inc., announced strong results from its second quarter. The company recorded a 53% increase in its revenues, driven primarily by its sizing tech and e-commerce platform powered by artificial intelligence. It also saw its…

MondayAug 26, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio Enhancement

The company has released key corporate and business updates and Q2 2024 financial results Clinical trials for both Alzheimer’s and Parkinson’s studies yielded encouraging data for lead compound buntanetap Buntanetap in combination with GLP-1 agonist dulaglutide Trulicity(R) showed increased potential to synergistically enhance cognition The company has obtained a patent and begun manufacturing of a new crystalline form of buntanetap, with improved properties Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), offered key business updates and announced financial results for the second quarter…

MondayAug 26, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901

A long-term preclinical study of Alzheimer’s Disease (“AD”) drug candidate INM-901 included four groups: untreated disease-free, INM-901-treated disease-free, placebo-treated Alzheimer’s Disease, and INM-901-treated Alzheimer’s Disease at two dosing levels The results showed that INM-901-treated AD groups displayed behavior trends similar to the untreated disease-free group, with a clear dose response observed in most assessments The drug has also shown a reduction in neuroinflammation and enhancement of neuronal function, with molecular data supporting behavioral study observations InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes…

FridayAug 23, 2024 10:00 am

How Health Technology Could Improve Customer Experience

Any business in the healthcare sector seeking to improve customer experience, popularly known as CX, may benefit from using health technology. Data from Forrester Research shows that 6% of brands that took part in the 2023 U.S. Customer Experience rankings saw increases in quality of customer experiences. 8x8’s chief technology officer, Bryan Martin, believes this may be because brands aren’t investing in processes and tools to enhance customer experiences. To boost customer experiences, healthcare organizations can concentrate on: Automation and Artificial Intelligence The use of manual processes is frustrating, not only for organizations but also to patients. Automation of an…

ThursdayAug 22, 2024 1:33 pm

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials

Two Phase 2 independently conducted clinical trials showed significant improvement in key biomarkers among ALS patients who were administered CNM-Au8 Biomarker and efficacy data was submitted to the Food and Drug Administration for a granted Type C meeting request, with the company targeting an accelerated approval pathway CEO Rob Etherington expressed optimism about CNM-Au8's potential as a new ALS treatment, and voiced hope that ALS patients will benefit sooner rather than later Clene recently presented its latest updates and findings at the Canaccord Genuity 44th Annual Growth Conference Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial…

WednesdayAug 21, 2024 10:00 am

Scientists Find Way to Boost Natural Killer Cells Targeting Pediatric Brain Cancer

Natural killer cells are white blood cells that eliminate cancer or other infected cells in the human body. Now a new study has looked into these cells’ ability to eliminate a certain type of cancer known as malignant rhabdoid tumor. This aggressive and rare type of brain cancer starts developing in a child’s kidneys, soft tissues or other organs. It mainly affects young children and babies. In some instances, natural killer cells can be overpowered by the cancer cells. Scientists at Florida State University may have found a way to enhance natural killer cells that target this pediatric cancer. The…

TuesdayAug 20, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast

Annovis Bio’s lead drug candidate buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients In a short-term Phase 2/3 study, buntanetap has been shown to work three times better than the standard of care in the market The company plans further clinical trials to validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, presented significant data and findings of its Phase 2/3 Alzheimer’s study of lead drug candidate buntanetap at the Alzheimer’s Association…

MondayAug 19, 2024 1:30 pm

UCSF Team Tests New Drug That Could Reverse Multiple Sclerosis

Multiple sclerosis is an autoimmune condition that affects an individual’s brain and spinal cord, causing symptoms that include difficulty walking or problems with one’s vision or balance. The condition’s mechanism of action involves using an individual’s immune system to attack the myelin, a protein and fatty substance that protects and surrounds nerve fibers. By damaging myelin, nerves aren’t able to carry electrical impulses from and to the brain. This damage also allows scar tissue known as sclerosis to form. This chronic disease of the central nervous system may, in some cases, lead to severe disability. Now, researchers at Contineum Therapeutics…

FridayAug 16, 2024 10:00 am

Enrollment for Medicare Advantage Differs Sharply in California Counties

In America, Medicare Advantage is increasing in popularity among beneficiaries of Medicare. Insurers under this version of Medicare offer lower premiums, with dental and vision coverage added on. Jointly, more than 50% of eligible recipients of Medicare are on private plans. However, a recent report from KFF determined that there were huge differences between enrollment in Medicare Advantage in the northern and southern counties of California. Data from the Centers for Medicare & Medicaid Services shows that market penetration for Medicare Advantage was considerably lower in northern counties in comparison to southern counties. The state of California differs from other…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast

AI Firms Gain Foothold in e-Commerce, Software, Healthcare Industries

Annovis Bio Inc. (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio Enhancement

InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901

How Health Technology Could Improve Customer Experience

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials

Scientists Find Way to Boost Natural Killer Cells Targeting Pediatric Brain Cancer

Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast

UCSF Team Tests New Drug That Could Reverse Multiple Sclerosis

Enrollment for Medicare Advantage Differs Sharply in California Counties

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search